Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Scinopharm Taiwan's Sloan Ratio for the quarter that ended in Jun. 2026 was -4.36%.
As of Jun. 2026, Scinopharm Taiwan has a Sloan Ratio of -4.36%, indicating the company is in the safe zone and there is no funny business with accruals.
Scinopharm Taiwan (TPE:1789) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Scinopharm Taiwan has a Sloan Ratio of -4.36%, indicating the company is in the safe zone and there is no funny business with accruals.
Scinopharm Taiwan Sloan Ratio % Related Terms
Scinopharm Taiwan Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Sloan Ratio % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Scinopharm Taiwan's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Scinopharm Taiwan's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 15.446 (Sep. 2025 ) + 41.281 (Dec. 2025 ) + 16.529 (Mar. 2026 ) + -35.528 (Jun. 2026 ) = NT$38 Mil.
Scinopharm Taiwan's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 25.177 (Sep. 2025 ) + 343.974 (Dec. 2025 ) + 199.631 (Mar. 2026 ) + 237.047 (Jun. 2026 ) = NT$806 Mil.
Scinopharm Taiwan's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -46.135 (Sep. 2025 ) + -82.055 (Dec. 2025 ) + -84.237 (Mar. 2026 ) + -16.792 (Jun. 2026 ) = NT$-229 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Sloan Ratio % of -4.36% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Sloan Ratio % too high?
Scinopharm Taiwan's current Sloan Ratio % is -4.36%. Overall, Scinopharm Taiwan has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Sloan Ratio % compare to ZTS?
Scinopharm Taiwan's Sloan Ratio % of -4.36% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Drug Manufacturers company?
A good Sloan Ratio % depends on the Drug Manufacturers industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Sloan Ratio % is -4.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.13, compared to a current price of NT$19.10 — trading 5.1% below its estimated fair value. The current Sloan Ratio % is -4.36%. Scinopharm Taiwan's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Sloan Ratio % is -4.36% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.10 is trading 5.1% below its estimated GF Value™ of NT$20.13.
GuruFocus considers Scinopharm Taiwan to be Fairly Valued.
Key valuation signals for TPE:1789:
Sloan Ratio %: -4.36%
GF Value™: NT$20.13 vs. price of NT$19.10 (5.1% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
69GF Score
Get the complete analysis for TPE:1789
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
